Keala Milles

Strong earnings and revenue growth encourage Goldman Sachs to upgrade Global Payments Inc GPN to a BUY rating; shares add 3%.

Cinemark share price jumped 6% on analyst's Bullish confidence. The stock has a much better outlook than its nearest competitor, AMC.

Wedbush analysts upgrade Dutch Bros Coffee to Overweight on Long-term growth potential, though it depends on the success of their aggressive expansion.

Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.

JP Morgan upgrades Macy's stock rating to Overweight on confidence that the retailer's strategies will succeed at improving its bottom line.

The price target for Walmart stock jumped from $145 to $160 on news that Evercore analysts upgraded WMT to Moderate Buy.

Financial analysts upgraded CIEN's rating to Strong Buy near the end of March as the company announced expansion into the emerging edge router market.

Medtronic hopes team reorganization and a new Nvidia partnership will help boost outlook and encourage a rating upgrade within the year.

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy

After Beyond Meat, Inc reported better-than-expected results investors may be interested in how other companies in the plant-based meat industry could compete.

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.

A court ruled that Medtronic infringed on Colibri patents.The financial toll from damages is heavy but may not endure as the data suggests MDT is strong.

MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million

Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.

These three AI/Cloud stocks are near historic lows but the industry is growing. As such, any of these could rebound; though it may take longer for some.

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

These stocks fell last year, which helped boost their dividends. Now around $10 a share each, they offer great value, but could also have more risk.

Tesla announced price cuts on popular models in order to boost sales, after several earnings misses. Hopefull this can build momentum to restore stock value

Despite a positive preliminary earnings report, Tmobile stock is slipping. This article investigates some of the factors that may be contributing to the dip.

Pepsi introduced a new lemon-lime beverage, "Starry" to somewhat poor reception, but that does not seem to affect long-term growth.

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.